2 weeks Ago By Defense World Staff
Ascendis Pharma A/S ( NASDAQ:ASND – Get Free Report ) is set to release its earnings data after the market closes on Thursday, November 14th. Analysts expect Ascendis Pharma A/S to post earnings of ($1.54) per share for the quarter.
Investors interested in listening to the company’s conference call can do so using this link . Ascendis Pharma A/S ( NASDAQ:ASND – Get Free Report ) last released its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.
05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51).
The business had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million.
On average, analysts expect Ascendis Pharma A/S to post $-7 EPS for the current fiscal year and $-4 EPS for the next fiscal year. Ascendis Pharma A/S Stock Performance NASDAQ ASND opened at $127.67 on Wednesday.
The stock has a 50 day moving average price of $131.91 and a 200-day moving average price of $132.90.
Ascendis Pharma A/S has a one year low of $86.54 and a one year high of $161.00.
The company has a market capitalization of $7.74 billion, a P/E ratio of -13.71 and a beta of 0.
66. Wall Street Analyst Weigh In Get Our Latest Stock Report on Ascendis Pharma A/S About Ascendis Pharma A/S ( Get Free Report ) Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD).
The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. See Also Five stocks we like better than Ascendis Pharma A/S Consumer Discretionary Stocks Explained Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025 Insider Trading – What You Need to Know Is Tesla’s Valuation a Bubble or Backed by Real Growth? What is the S&P/TSX Index? Trucking Stocks Led the Pack Last Week: Can They Keep Rolling? Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter .
.
